Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan

International Journal of STD and AIDS

Volumn 22, Issue 11, 2011, Pages 617-620

  Hsieh, S M ^a   Chang, S Y ^a   Hung, C C ^a   Sheng, W H ^a   Chen, M Y ^a   Chang, S C ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Darunavir; Genotypic resistance; HIV 1; Protease inhibitors; Tipranavir

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR PLUS TIPRANAVIR; TIPRANAVIR;

ADULT; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; TAIWAN; VIRUS ISOLATION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PYRIDINES; PYRONES; SULFONAMIDES; TAIWAN; TREATMENT FAILURE;

EID: 81355132905     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009007     Document Type: Article

References (12)

1. Temesgen Z, Feinberg J. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis 2007;45:761-69
2. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomized open-label trials. Lancet 2006;368: 466-75
3. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-78
4. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med 2008;16:62-68
5. Chang SY, Chen MY, Lee CN, et al. Trend of antiretroviral drug resistance in treatment-nayi{cyrillic}ve patients with HIV-1 infection in Taiwan. J Antimicrob Chemother 2008;61:689-93
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Department of Health and Human Services (DHHS). See http://www.aidsinfo.nih.gov/ContentFiles/AdultandadolescentGL.pdf (last accessed 29 January 2008)
7. Baxter JD, Schapiro JM, Boucher CA, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.J Virol 2006;80:10794-801
8. Winters B, van der Borght K, Craenenbroeck E, et al. Accuracy and Correlation of Response Predictions Based on 4 Methodologies to Interpret Darunavir Resistance in Patients Receiving Darunavir-containing Regimens in the POWER Studies. Cascais: 5th European HIV Drug Resistance Workshop, 2007 (Abstract 72)
9. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-nayi{cyrillic}ve HIV-1-infected persons in 10 US cities. J Infect Dis 2004;189:2174-80
10. Wensing AMJ, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in nai{dotless}̈ve persons in Europe. J Infect Dis 2005;192:958-66
11. Baxter J, Bhatti L, Coakley E, et al. Genotypic Susceptibility to Tipranavir and Darunavir in a Cohort of Treatment-experienced Patients. Glasgow: 9th International Congress on Drug Therapy in HIV Infection, 2008
12. Piliero PJ, Bhatti L, Coakley E, et al. Genotypic and Phenotypic Susceptibility to Tipranavir of HIV-1 Isolates in Treatment-experienced Patients. Glasgow: 9th International Congress on Drug Therapy in HIV Infection, 2008